Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals

Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals

Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.

Inhibition of microRNA‐24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia

Raymond Ng, Heng Wu, Hong Xiao, Xin Chen, Holger Willenbring, Clifford J. Steer, Guisheng Song – 28 March 2014 – The incidence of nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia, with their associated risks of endstage liver and cardiovascular diseases, is increasing rapidly due to the prevalence of obesity. Although the mechanisms of NAFLD have been studied extensively, the underlying pathogenesis and the role of microRNAs in this process remain relatively unclear.

Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection

Antonio Riva, Melissa Laird, Armanda Casrouge, Arvydas Ambrozaitis, Roger Williams, Nikolai V. Naoumov, Matthew L. Albert, Shilpa Chokshi – 26 March 2014 – The pathogenesis of hepatitis C virus (HCV) infection is strongly influenced by the nature of the host's antiviral immunity. Counterintuitively, elevated serum concentrations of C‐X‐C chemokine 10 (CXCL10), a potent chemoattractant for antiviral T‐cells and NK‐cells, are associated with poor treatment outcomes in patients with chronic HCV.

Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice

Hyon‐Seung Yi, Young‐Sun Lee, Jin‐Seok Byun, Wonhyo Seo, Jong‐Min Jeong, Ogyi Park, Gregg Duester, Takeshi Haseba, Sun Chang Kim, Keun‐Gyu Park, Bin Gao, Won‐Il Jeong – 26 March 2014 – The important roles of retinols and their metabolites have recently been emphasized in the interactions between hepatic stellate cells (HSCs) and natural killer (NK) cells. Nevertheless, the expression and role of retinol metabolizing enzyme in both cell types have yet to be clarified. Thus, we investigated the expression of retinol metabolizing enzyme and its role in liver fibrosis.

Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: A randomized controlled trial

Karin E. Koopman, Matthan W.A. Caan, Aart J. Nederveen, Anouk Pels, Mariette T. Ackermans, Eric Fliers, Susanne E. Fleur, Mireille J. Serlie – 26 March 2014 – American children consume up to 27% of calories from high‐fat and high‐sugar snacks. Both sugar and fat consumption have been implicated as a cause of hepatic steatosis and obesity but the effect of meal pattern is largely understudied. We hypothesized that a high meal frequency, compared to consuming large meals, is detrimental in the accumulation of intrahepatic and abdominal fat.

Engineering liver

Linda G. Griffith, Alan Wells, Donna B. Stolz – 26 March 2014 – Interest in “engineering liver” arises from multiple communities: therapeutic replacement; mechanistic models of human processes; and drug safety and efficacy studies.

Subscribe to